摘要
目的 探讨麝香保心丸联合美托洛尔治疗老年气滞血瘀型冠状动脉粥样硬化性心脏病心绞痛的疗效及对IL-33/ST2信号通路的影响。方法 选取2021年1月至2023年1月沈阳市第二中医医院收治的气滞血瘀型老年冠状动脉粥样硬化性心脏病心绞痛患者78例作为研究对象,随机分为对照组与观察组,各39例。对照组采用美托洛尔治疗,观察组在对照组基础上联合麝香保心丸治疗,比较两组患者的治疗效果。结果 观察组治疗有效率高于对照组(P<0.05);治疗1个月后观察组心绞痛发作次数、心绞痛持续时间、心绞痛视觉模拟评分法(VAS)评分优于对照组(P<0.05);治疗1个月后观察组血清白细胞介素-33(IL-33)、生长刺激表达基因2蛋白(ST2)水平低于对照组(P<0.05)。结论 麝香保心丸联合美托洛尔治疗老年气滞血瘀型冠状动脉粥样硬化性心脏病心绞痛临床疗效显著,可通过调控IL-33/ST2信号通路减轻炎症反应,有效改善心绞痛症状。
Objective To explore the efficacy of Shexiang Baoxin Pill combined with metoprool in the treatment of senile coronary atherosclerotic heart disease with angina pectoris caused by qi stagnation and blood stasis and its influence on IL-33/ST2 signaling pathway.Methods A total of 78 elderly patients with coronary atherosclerotic heart disease angina with Qi-stagnation and blood-stasis type admitted to Shenyang Second Hospital of Traditional Chinese Medicine from January 2021 to January 2023 were selected as the study objects and randomly divided into control group and observation group,with 39 cases in each group.The control group was treated with metoprolol,and the observation group was treated with Shexiang Baoxin pill on the basis of the control group.The therapeutic effect of the two groups was compared.Results TThe effective rate of the observation group was higher than that of the control group(P<0.05).After 1 month of treatment,angina attack frequency,angina duration and angina VAS score in observation group were better than those in control group(P<0.05).After 1 month of treatment,the serum levels of IL-33 and ST2 in the observation group were lower than those in the control group(P<0.05).Conclusion Shexiang Baoxin Pill combined with metoprool has significant clinical effect in the treatment of elderly coronary atherosclerotic heart disease angina pectoris with qi stagnation and blood stasis.It can reduce inflammatory response and effectively improve angina pectoris symptoms by regulating IL-33/ST2 signaling pathway.
作者
吕晓莉
董川
LV Xiao-Li;DONG Chuan(Department of Cardiology,Shenyang Second Hospital of Traditional Chinese Medicine,Shenyang 110101,China)
出处
《中国药物经济学》
2024年第9期51-53,56,共4页
China Journal of Pharmaceutical Economics
